Available company data, source links and archived checks for Zydus Lifesciences Ltd.. Read each source and date: a past check is not a fresh review, and some earlier figures have incomplete source details.
Quarter ended 2026-06-30 · consolidated · Company filing
| Quarter | Revenue / income | YoY | Profit | YoY | Net margin | Source |
|---|---|---|---|---|---|---|
| Jun 2026 | Revenue: ₹8,017 cr | +22.0% | Net profit: ₹990 cr | -34.9% | 12.4% | Company filing source |
| Mar 2026 | Revenue: ₹7,587 cr | +16.2% | Net profit: ₹1,341 cr | +7.8% | 17.7% | Company filing source |
| Dec 2025 | Revenue: ₹6,864 cr | — | Net profit: ₹1,023 cr | — | 14.9% | Company filing source |
| Sep 2025 | Revenue: ₹6,123 cr | — | Net profit: ₹1,239 cr | — | 20.2% | Company filing source |
| Jun 2025 | Revenue: ₹6,574 cr | +5.9% | Net profit: ₹1,521 cr | +2.6% | 23.1% | Company filing source |
| Mar 2025 | Revenue: ₹6,528 cr | — | Net profit: ₹1,244 cr | — | 19.1% | Company filing source |
YoY means change from the same quarter a year earlier. — means no comparable figure is available. Older entries with incomplete source details have not been revalidated under the current checks.
Full-year FY2026 revenue was Rs 26,720 crore and net profit was Rs 5,040 crore.
Gross margin for the June 2026 quarter was 73.4%, up from 72.3% in the same quarter last year.
Promoter holding is 75.01% with zero shares pledged as of June 2026.
Revenue for the June 2026 quarter was Rs 8,017 crore, up 24.0% from Rs 6,467 crore in the same quarter last year.
Zydus received final USFDA approval for Ascorbic Acid Injection with 180-day Competitive Generic Therapy exclusivity.
Keep its available filings, dated fact checks and disclosure alerts together. Your saved country sets your market and its research schedule.
Start free — first week on us →Company data and archived claim checks are shown with available sources. Check the source and date before relying on a figure. This is not investment advice or a recommendation. Investment in securities markets is subject to market risks. Research on this site is produced with substantial use of AI. Terms, disclosures and grievances